Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Autor: Stefano Iacobelli, Malgorzata Foszczynska-Kloda, Soo-Chin Lee, Richard A. Michaelson, Juan Lacava, Raymond Smith, Vichien Srimuninnimit, Mauricio Kotliar, William Audeh, Damir Vrbanec, Young-Hyuck Im, Paola Edith Price, Maria Del Pilar, Barbara Bower, Tadeusz Pienkowski, Jedzada Maneecahvakajorn, Seppo Pyrhoenen, Alexander Marmé, Saverio Cinieri, Vladimir Semiglazov, Luciano Latini, Luis Miguel, Thitiya Sirisinha, Mario Matwiejuk, Jose Luiz Pedrini, John Allan Ellerton, Maik Hauschild, Xiaojia Wang, Christoph Maintz, Joohyuk Sohn, Estefania Monturus, Kenjiro Aogi, Eugeny Gotovkin, Ron Blachy, Douglas Otero Reye, Rita Blanchard, Bahriye Aktas, Adam Knott, Norberto Batista Lopez, L Roman, Reiki Nishimura, Piotr Tomczak, Duncan Wheatley, Emilio Alba Conejo, Yoshinori Itoh, Giraldo Kato, Petar Stefanovski, Rosa Jochim, Christoph Thomssen, Brigitte Van Eyll, Yutaka Tokuda, S O'Reilly, Paulette Blanchet, Ion Boiangiu, Nikola Vasev, Sherko Kümmel, Julie Taguchi, Do Youn Oh, David Miles, Jurandyr Andrade, Nora Giacomi, Volkmar Mueller, Eduardo Côrtes, Paula Klein, Eleonora Restuccia, Xuenong Ouyang, Leanne Budde, Andre Kallab, Elżbieta Starosławska, Takayuki Ueno, Taral Patel, Jun Horiguchi, Gilson Delgado, Sue Prill, Carol Peterson, Lourdes Calvo, Andreas Kirsch, Gustavo Ismael, Liwei Wang, Veena Charu, Dino Amadori, Pirkko Kellokumpu-Lehtinen, Brooke R. Daniel, Frank Senecal, Sanjay Yadav, Vera Gorbunova, Mikhail Kopp, Patrapim Sunpaweravong, Hiroji Iwata, Frank Priou, Kazuhiko Nakagami, Alejandra Perez, Michael R. Clemens, Marcus Schmidt, Denise A. Yardley, Birgitta Wesenberg, Priscilla Caguioa, Haruki Ogata, An Nguyen, Sung Bae Kim, Tsz-Kok Yau, Vladimir Merculov, Mikhail Lichinitser, Valorie Chan, Yoshiaki Rai, Neville Davidson, Walter E. Aulitzky, Gloria Martinez, Koji Takeda, Sherene Loi, Junichiro Watanabe, Louis Fehrenbacher, Gunta Purkalne, Shaker R. Dakhil, Claudia Schumacher, Rizvana Ahmad, Winnie Yeo, Christine Brezden-Masley, Alison Jones, Seock-Ah Im, Zetina Toache, Jeffrey Hargis, Celia Tosello, Tania Soria, Catia Angiolini, Maria De Fatima Gaui, Ravi Patel, Christopher Lobo, Andreas Schneeweiss, Priyanka Sharma, Cesar Estuardo, Randall Thomas, Adam Brufsky, Virote Sriuranpong, Zhenzhou Shen, Sandra Franco, Clive Mulatero, Wojciech Polkowski, Maria Alejandra Bartoli, Shigehira Saji, Patrick J. Flynn, Kimberly L. Blackwell, Gladys Rodriguez, Robert Robles, Timothy J. O'Rourke, Fabio Franke, Gabriel Tellez-Trevilla, Robert R. Carroll, Laura Biganzoli, Cheng Ying, Peter A. Kaufman, Mark Karwal, Mirta Varela, Darcy Spicer, Jonathan Polikoff, Roberto Hegg, Jungsil Ro, Pedro Sánchez-Rovira, Takahiro Nakayama, Edda Simoncini, María Bianconi, Liljana Kostovska-Maneva, Hugo Castro, Elza Grincuka, Jeff Neidhart, Anne Robinson, Nathan B. Green, Robert Hermann, Laura Assersohn, Teresa Gamucci, Dennis Tudtud, Nobuaki Sato, Antonio Gonzalez Martin, Victor Hugo Alencar, Jess Armor, Bruno Coudert, Nuria Ribelles, Eva Ciruelos, Daniel Cubero, Iveta Kudaba, Eduardo Cronemberger, Norikazu Masuda, Norio Kohno, Sergio J Azevedo, Vadim Shirinkin, Miguel Gil I Gil, Serafin Morales, Hirofumi Fujii, Chris Gallagher, Hernandez Monroy, Katsumasa Kuroi, Rodrigo Moura, Richy Agajanian, Zeljko Soldic, Jean-Marc Ferrero, Kenichi Inoue, Mark C. Benyunes, Davi Jendiroba, Filippo Montemurro, Masahiro Kashiwaba, Robert Quackenbush, Koichiro Tsugawa, Paulo M. Hoff, Eva-Maria Grischke, Susana De La Cruz, Vincent Hansen, Marianna Bitina, Carolyn B. Hendricks, Javier Cortes, Zee Wan Wong, Igor Kiselev, David Waterhouse, Javier Hornedo Muguiro, Mario Campone, Marianne Just, Emma Clark, Rodrigo Pereira, Sandra M Swain, Ruemu E. Birhiray, Helio Pinczowski, Wichit Arpornwirat

Publikováno v: The Lancet. Oncology. 21(4)

Summary Background CLEOPATRA was a phase 3 study comparing the efficacy and safety of pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with HER2-positive metastatic breast cancer. In the primary analysis and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e284b6f4b09c71b9922a7f657773bd0
https://pubmed.ncbi.nlm.nih.gov/32171427